Invention Publication
- Patent Title: COMBINATION THERAPY WITH A MEK INHIBITOR AND A SRC INHIBITOR FOR THE TREATMENT OF COLORECTAL CANCER
-
Application No.: US18589576Application Date: 2024-02-28
-
Publication No.: US20240197746A1Publication Date: 2024-06-20
- Inventor: Ravid STRAUSSMAN , Nancy GAVERT , Yaara ZWANG
- Applicant: Yeda Research and Development Co. Ltd. , The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center
- Applicant Address: IL Rehovot
- Assignee: Yeda Research and Development Co. Ltd.,The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center
- Current Assignee: Yeda Research and Development Co. Ltd.,The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center
- Current Assignee Address: IL Rehovot; IL Tel-Aviv
- Main IPC: A61K31/52
- IPC: A61K31/52 ; A61K31/4184 ; A61K31/4745 ; A61K31/496 ; A61K31/5025 ; A61K31/506 ; A61K31/513 ; A61K31/517 ; A61P35/00 ; C12N5/071 ; C12N5/09 ; G01N33/50
Abstract:
A method of treating colorectal cancer (CRC) is provided. The method comprises administering to a subject in need thereof a therapeutically effective amount of a Mitogen/extracellular signal-regulated kinase (MEK) inhibitor and a SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase (SRC) inhibitor, wherein cancer cells of the subject express an amount of SRC p419 above a predetermined level and do not express a KRAS G12 mutation, thereby treating the CRC.
Information query
IPC分类:
